New hope for advanced skin cancer: targeted pill tested in china
NCT ID NCT06880848
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tested a drug called sonidegib in 160 Chinese adults with a type of advanced skin cancer (basal cell carcinoma) that could not be treated with surgery or radiation. The drug is taken as a capsule and works by blocking signals that help cancer grow. The main goal was to see how many patients' tumors shrank or disappeared.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sonidegib (a targeted cancer drug taken as a capsule)
What this could lead to
If successful, this could provide a new treatment option for Chinese patients with advanced basal cell carcinoma who cannot have surgery or radiation.
What could go wrong
This is a single-arm, Phase IV study without a placebo or comparison group, so results may be less definitive. Side effects from sonidegib can include muscle spasms, hair loss, and taste changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, BASAL CELL (BCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital
Beijing, China, 100034, China